The Institutional Investor Approach to APAC Life Science Real Estate
Asia Pacific’s rise draws investor attention
The global economy is undergoing a fundamental rebalancing. By 2040, the Asia Pacific (APAC) region is expected to account for over 40% of the world’s gross domestic product (GDP)1, and discerning institutional investors are already making moves to take advantage of this structural shift.
Yet, not all APAC markets carry equal risk profiles. That diversity is a structural advantage, offering investors meaningful exposure to highly stable, AAA-rated sovereign markets such as Singapore, which can provide resilience during downturns. Combined with strong government initiatives to build domestic biomedical capabilities, APAC markets are quickly positioning themselves as regional life science hubs that investors can underwrite with confidence.
That said, identifying opportunities is only the beginning, especially in APAC, where industry reputation carries more weight than balance sheets alone. Investors who understand the dynamics underpinning APAC markets will be better positioned to access quality assets.
Prioritising tenant quality as a risk management strategy
Institutional investors gravitate towards established life science organisations for their favourable tenant profiles and lease structures. In APAC, this consists of reputable biopharmaceutical and healthcare multinationals with verifiable track records such as Pfizer, Sanofi, AstraZeneca and Roche. As durable income stability is prioritised over short-term yield maximisation, leases held by major life science institutions are generally viewed as more resilient than those held by speculative tenants.
The gravitation towards reputable tenants is also shaped by APAC's historically lower venture capital penetration relative to the United States (US) and Europe. As a result, life science companies in APAC have traditionally operated under more conservative funding conditions, requiring stronger balance sheets and clearer pathways to commercialisation to secure both private and public funding. While this creates higher barriers to entry, the selective operating environment tends to favour businesses with stronger financial fundamentals and clearer commercial viability.
Life science leases built to last
Perhaps one of the most compelling attributes of life science real estate is the predictability of the income profile of this institutional asset class. As life science tenants operate within healthcare and pharmaceutical ecosystems that are subject to extensive regulation, their compliance obligations form an operational lock-in that translates directly into lease stability.
For example, China’s latest Good Manufacturing Practice (GMP) for Medical Devices2 will govern everything from infrastructure to production documentation from 1 November 2026. Crucially, GMP certification is tied to physical premises, making relocation far more complex than simply finding a cheaper space, as doing so may trigger a full recertification process that can cost life science tenants significant time and capital.
This structural stickiness is a feature of life science real estate across the region reinforced by rapidly expanding pipelines. In 2025 alone, mainland China reached a record high of 76 innovative drug approvals and 157 deals in innovative medicine licence-out transactions valued at US$135.7 billion3. These dynamics enable institutional investors to gain exposure to Chinese pharmaceutical innovation without the accompanying risk of full domestic market participation.
Institutional life science demand shifting towards APAC
Nowhere are the effects of this expanding innovation pipeline felt more keenly than in Singapore, where nine out of the top 10 global biopharma companies and eight out of the top 10 MedTech firms have established a presence in the city-state. Growing alongside these multinationals is a vibrant startup ecosystem with nearly 500 biomedical startups attracting over US$3 billion in venture capital funding4.
“Increasingly, APAC is being recognised as a core rather than satellite position, especially when markets such as Singapore offer stability and tenant quality that is becoming harder to find elsewhere. Investors who move in early will be best positioned to benefit in the long run.” - Bart Price, Vita Partners CEO
This stands in contrast with major Western life science markets, where hubs such as Boston and the San Francisco Bay Area recorded laboratory vacancy rates exceeding 30% in 2026 after the US’ National Institutes of Health (NIH) cancelled billions of dollars in research grants5.
Capture your investment opportunity
While opportunities in APAC commercial real estate investment are evident, investment windows can narrow without warning. Explore how APAC life science real estate can strengthen your portfolio's income profile and long-term resilience by speaking with Vita Partners.
References
- Oxford Economics Forecasting. 6 August 2024.
- China Med Device - China’s New GMP for Medical Devices: What Overseas Manufacturers Need to Know. 2 February 2026.
- Shaun Brodie, Cushman & Wakefield - Life science update for investors — Q1 2026. 26 March 2026.
- Melvin Lin, CBRE - Life Sciences Real Estate in Singapore — Emerging Opportunities in a Mature Market. 10 June 2024.
- Diana Olick, CNBC - Life sciences lab real estate is clawing back from disaster. Here’s what that means for investors. 22 April 2026.